Israel Englander Acadia Pharmaceuticals Inc Transaction History

Millennium Management LLC

$224 Billion
Q1 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Millennium Management LLC holds 51,300 shares of ACAD stock, worth $833,625. This represents 0.0% of its overall portfolio holdings.

Number of Shares

51,300

Previous 1,764,678 97.09%

Holding current value

$833,625

Previous $55.3 Million 98.28%

% of portfolio

0.0%

Previous 0.02%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$17.79 - $30.86 $6.06 Million - $10.5 Million	340,666 Added 19.3%	2,105,344 $38.9 Million
Q4 2023 Feb 14, 2024	BUY	$20.78 - $31.77 $26.5 Million - $40.6 Million	1,276,906 Added 261.78%	1,764,678 $55.3 Million
Q2 2023 Aug 14, 2023	SELL	$17.8 - $25.65 $22.5 Million - $32.4 Million	-1,264,241 Reduced 72.16%	487,772 $11.7 Million
Q1 2023 May 15, 2023	BUY	$16.32 - $20.92 $8.97 Million - $11.5 Million	549,684 Added 45.72%	1,752,013 $33 Million
Q4 2022 Feb 14, 2023	BUY	$14.2 - $18.63 $11.8 Million - $15.5 Million	833,651 Added 226.12%	1,202,329 $19.1 Million

Q3 2022 Nov 14, 2022	SELL	$14.11 - $18.27 $6.85 Million - $8.87 Million	-485,599 Reduced 56.84%	368,678 $6.03 Million
Q2 2022 Aug 15, 2022	SELL	$13.01 - $27.22 $3.03 Million - $6.33 Million	-232,612 Reduced 21.4%	854,277 $12 Million
Q1 2022 May 16, 2022	BUY	$20.94 - $27.5 $10.1 Million - $13.3 Million	483,876 Added 80.24%	1,086,889 $26.3 Million
Q4 2021 Feb 14, 2022	BUY	$16.79 - $27.09 $9.95 Million - $16 Million	592,403 Added 5583.44%	603,013 $14.1 Million
Q3 2021 Nov 15, 2021	SELL	$15.78 - $24.77 $1.76 Million - $2.76 Million	-111,321 Reduced 91.3%	10,610 $176,000
Q2 2021 Aug 16, 2021	BUY	$19.4 - $27.42 $2.14 Million - $3.02 Million	110,131 Added 933.31%	121,931 $2.97 Million
Q1 2021 May 17, 2021	SELL	$25.02 - $54.99 $8.89 Million - $19.5 Million	-355,311 Reduced 96.79%	11,800 $304,000
Q4 2020 Feb 16, 2021	SELL	$41.04 - $56.79 $9.21 Million - $12.7 Million	-224,421 Reduced 37.94%	367,111 $19.6 Million
Q3 2020 Nov 16, 2020	SELL	$36.42 - $57.0 $8.66 Million - $13.6 Million	-237,900 Reduced 28.68%	591,532 $24.4 Million
Q2 2020 Aug 14, 2020	BUY	$39.26 - $52.73 $20.5 Million - $27.5 Million	521,586 Added 169.43%	829,432 $40.2 Million
Q1 2020 May 14, 2020	SELL	$31.65 - $46.87 $21.5 Million - $31.9 Million	-680,467 Reduced 68.85%	307,846 $13 Million
Q4 2019 Feb 14, 2020	SELL	$36.21 - $51.4 $1.18 Million - $1.67 Million	-32,551 Reduced 3.19%	988,313 $42.3 Million
Q3 2019 Nov 14, 2019	BUY	$22.22 - $44.01 $11.5 Million - $22.8 Million	517,029 Added 102.62%	1,020,864 $36.7 Million
Q2 2019 Aug 15, 2019	SELL	$23.32 - $28.12 $225,621 - $272,061	-9,675 Reduced 1.88%	503,835 $13.5 Million
Q2 2019 Aug 14, 2019	BUY	$23.32 - $28.12 $4.84 Million - $5.83 Million	207,349 Added 67.73%	513,510 $23.3 Million
Q1 2019 May 14, 2019	SELL	$16.17 - $27.38 $9.69 Million - $16.4 Million	-599,255 Reduced 66.19%	306,161 $8.22 Million
Q4 2018 Feb 14, 2019	BUY	$14.32 - $22.92 $6.97 Million - $11.2 Million	486,673 Added 116.22%	905,416 $14.6 Million
Q3 2018 Nov 14, 2018	SELL	$13.03 - $21.81 $3.41 Million - $5.71 Million	-261,881 Reduced 38.48%	418,743 $8.69 Million
Q2 2018 Aug 14, 2018	BUY	$15.07 - $22.34 $290,338 - $430,402	19,266 Added 2.91%	680,624 $10.4 Million
Q1 2018 May 15, 2018	BUY	$22.47 - $32.33 $12.9 Million - $18.6 Million	574,577 Added 662.1%	661,358 $14.9 Million
Q4 2017 Feb 14, 2018	BUY	$26.84 - $39.14 $674,006 - $982,883	25,112 Added 40.72%	86,781 $2.61 Million
Q3 2017 Nov 14, 2017	BUY	$29.49 - $38.37 $1.82 Million - $2.37 Million	61,669	61,669 $2.32 Million

Others Institutions Holding ACAD

# of Institutions

299

Shares Held

158M

Call Options Held

1.88M

Put Options Held

688K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.63B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account